Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials

Although immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis have improved the survival of patients with advanced non-small cell lung cancer (NSCLC), their efficacy in EGFR-mutated NSCLC is largely restricted in either first- or more advanced-line settings [1,2]. Previous studies have reported that co-mutations have profound impacts on the efficacy of ICIs [3]. Most EGFR-mutated NSCLC patients also have other mutations [4], but how these co-mutation patterns influence the effectiveness of ICIs is unclear.